CHRNA6抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CHRNA6 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of SH-SY5Y cells using CHRNA6 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of SK-N-SH cells using CHRNA6 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using CHRNA6 mouse mAb with DAB staining.    

  
  

The CHRNA6 antibody targets the α6 subunit of the nicotinic acetylcholine receptor (nAChR), encoded by the *CHRNA6* gene. This subunit forms ligand-gated ion channels involved in neurotransmission, particularly in dopaminergic pathways. CHRNA6 is predominantly expressed in the central nervous system, including regions like the ventral tegmental area and substantia nigra, where it modulates dopamine release. Its role in regulating reward and addiction mechanisms links it to neurological and psychiatric disorders, such as Parkinson’s disease, nicotine dependence, and substance abuse.

CHRNA6 antibodies are essential tools for studying the protein's expression, localization, and function. They enable detection via techniques like Western blotting, immunohistochemistry, or immunofluorescence, aiding research into nAChR-related signaling pathways. These antibodies also help explore genetic variants of *CHRNA6* associated with disease susceptibility or behavioral traits. For instance, studies use them to investigate how α6 subunit dysfunction impacts dopamine signaling or addiction vulnerability.

Commercially available CHRNA6 antibodies are typically raised in hosts like rabbits or mice, often validated for specificity against recombinant or native proteins. Researchers must confirm cross-reactivity and optimal experimental conditions, as nAChR subunits share structural homology. Proper validation ensures reliability in distinguishing CHRNA6 from related subunits (e.g., α4 or β2), critical for accurate mechanistic insights. Overall, CHRNA6 antibodies are pivotal in advancing neuropharmacology and addiction research.